@Article {Gaisl1901526，作者= {Gaisl，Thomas和Rejmer，Protazy和Thiel，Sira和Haile，Sarah R.和Osswald，Martin和Roos，Malgorzata和Bloch，Konrad E.和Stradling，John R.和Kohler，Malcolm}，标题= {CPAP治疗次优依从性对阻塞性睡眠呼吸暂停的症状：A随机，双盲，受控试验}，Elocation-Id = {1901526}，年= {2019}，Doi = {10.1183 / 13993003.01526出版商= {欧洲呼吸社会}，摘要= {介绍188bet官网地址连续正气道压力（CPAP）目前是患睡眠呼吸暂停（OSA）患者嗜睡的选择，然而，遵守往往被认为是次优。我们调查了次优CPAP使用对OSA患者客观和主观睡眠参数的影响。本2周，平行，双盲，随机对照试验我们注册了中度至严重的OSA患者的过度前期- 处理白天嗜睡（Epworth-Sleepiness-Scale [Ess] Score \> 10分），他们在至少12个月内获得了次优CPAP遵守（意味着夜间使用时间3 {\ TextEndash} 4 H）。患者通过最小化分配给子治疗性CPAP（{\ textquotedblleft} sham-cpap {\ textquotedblright}）或CPAP（治疗CPAP）的延续。与历史前沿的贝叶斯分析计算出优越性的后验概率。2016年5月和2018年11月之间的结果，总共分配了57例（60岁）（60 {\ Textpm} 8年，79 \％Men，93 \％白种人）。52完成研究的谁（每个手臂50 \％）被列入最终分析。与持续治疗CPAP相比，在假CPAP组中，未经调整的ESS评分增加为+ 2.4点（95 \％CI + 0.6至+4.2; p = 0.01）。对于Shem CPAP的治疗性CPAP优越性的概率为90.4 \％，对于收缩系统的90.1±\％，舒张压的80.3 \％。结论患有中度至严重的OSA和白天嗜睡的患者仍然是大量的好处从次优CPAP遵守中，尽管他们不像他们遵守更多一样。 Whether a similar statement can be made for even lower adherence levels remains to be established in future trials.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Gaisl reports personal fees from Bayer AG (consulting), outside the submitted work.Conflict of interest: Dr. Rejmer has nothing to disclose.Conflict of interest: Dr. Thiel has nothing to disclose.Conflict of interest: Dr. Haile has nothing to disclose.Conflict of interest: Dr. Osswald has nothing to disclose.Conflict of interest: Dr. Roos has nothing to disclose.Conflict of interest: Dr. Bloch has nothing to disclose.Conflict of interest: Dr. Stradling reports personal fees from Bayer AG, personal fees from ResMed, outside the submitted work.Conflict of interest: Dr. Kohler reports personal fees from Bayer AG, grants from University of Zurich, grants from Lunge Zurich, outside the submitted work.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2019/12/04/13993003.01526-2019}, eprint = {//www.qdcxjkg.com/content/early/2019/12/04/13993003.01526-2019.full.pdf}, journal = {European Respiratory Journal} }